BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson's DiseaseGlobeNewsWire • 05/18/26
BioVie Inc. (BIVI) Discusses Bezisterim's Mechanism of Action and Its Potential in Addressing Parkinson's Disease Pathology TranscriptSeeking Alpha • 05/09/26
BioVie to Host Virtual KOL Event to Discuss the Phase 2 Study of Bezisterim for the Treatment of Parkinson's Disease ahead of Topline Data in 2Q26, on May 7, 2026GlobeNewsWire • 04/27/26
BioVie Announces Abstract Accepted for Presentation at the 2026 American Academy of Neurology Annual MeetingGlobeNewsWire • 04/14/26
BioVie Inc. (BIVI) Discusses Clinical Progress of Bezisterim Targeting Inflammation in Parkinson's, Alzheimer's, and Long COVID TranscriptSeeking Alpha • 03/05/26
Halper Sadeh LLC Encourages BioVie Inc. Shareholders to Contact the Firm to Discuss Their RightsGlobeNewsWire • 02/12/26
BioVie hits enrolment milestone in early Parkinson's trial, data due later this yearProactive Investors • 01/16/26
HALPER SADEH LLC ENCOURAGES BIOVIE INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTSPRNewsWire • 12/24/25
BioVie Inc. (BIVI) Discusses Clinical Progress of Lead Drug Candidates Targeting Parkinson's, Alzheimer's, and Liver Disease TranscriptSeeking Alpha • 12/10/25
BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection SyndromesGlobeNewsWire • 08/13/25
BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and GerontologyGlobeNewsWire • 07/24/25